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Introduction
Gain-of-function mutations in IFIH1 were identified in
Aicardi-Goutières syndrome (AGS), a rare neuroimmuno-
logical disorder associated with elevated levels of type I
interferon and characterized by leucoencephalopathy,
brain atrophy and intracranial calcifications leading to pro-
found intellectual disability, spasticity and dystonia. IFIH1
functions as an intracellular innate immune receptor that
senses viral nucleic acids and leads to the induction of
type I interferon and proinflammatory cytokines.
Objectives
We aimed to identify the underlying genetic defect in a
16-year-old girl with severe early-onset and refractory
systemic lupus erythematosus (SLE), IgA-deficiency and
mild lower limb spasticity without neuroradiological
manifestations.
Methods
Whole-exome sequencing was performed on the index
patient and her parents. Extensive immunological analy-
sis was performed on serum and on peripheral blood
mononuclear cells (PBMC) of the patient.
Results
We independently identified the same de novo
p. Arg779His IFIH1 mutation in a young patient with
severe refractory SLE with antiphospholipid syndrome
as was described in two patients with an AGS pheno-
type without major immunological manifestations. The
index patient in our study, a girl of European Belgian
ancestry, was initially seen before the age of 1 year with
frequent respiratory infections. Immunological testing
revealed IgA-deficiency. By the age of 2.5 years she
developed spasticity of the lower limbs, with normal
cognitive and clinical development. Magnetic resonance
imaging (MRI) of the brain and spine showed no
abnormalities. At the age of 8 years the patient was
diagnosed with SLE with secondary antiphospholipid
syndrome. Clinically, she manifested arthritis, livedo
rash, necrotizing cutaneous vasculitis and she developed
a deep venous thrombosis. Blood analysis showed a
marked inflammatory response, complement activation
and highly increased levels of anti-dsDNA, anticardioli-
pin and anti-thyroid antibodies. Further analysis also
showed elevated serum levels of interferon a and upre-
gulation of IFIH1 on the RNA-level in patient PBMC.
Single-photon emission computed tomography (SPECT)
of the brain showed no signs of intracerebral vasculitis
and brain CT and MRI did not show any microcalcifica-
tions or other abnormalities. Despite systemic immuno-
suppressive treatment, signs of autoimmune activation
remained with persistently increased levels of circulating
autoantibodies and complement activation, as well as
persistently elevated interferon a in serum and IFIH1
upregulation in patient PBMC. Attempts at decreasing
immunosuppressive medication were associated with
disease flares. The lower limb spasticity has stabilized,
cognitive functioning has remained excellent and all
neuroradiological examinations have remained normal.
Conclusion
This finding adds a new gene association to Mendelian
lupus and greatly extends the disease spectrum associated
with mutations in IFIH1, ranging from AGS to SLE with
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or without neuroradiological manifestations. This marked
phenotypic heterogeneity, despite an identical mutation,
demonstrates the importance of modifying genetic or
environmental factors in type I interferon-dependent
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